Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Announces Key Executive Transitions and New Leadership Appointment
Summary
On July 23, 2024, Terns Pharmaceuticals, Inc. announced the transition of key executive roles. Mark Vignola, Ph.D., the Chief Financial Officer, will resign on February 1, 2025, with a severance package of $475,000 and additional bonuses. Bryan Yoon, Esq., the Chief Operating Officer, will resign on September 3, 2024, receiving a severance of $490,700 and other bonuses. Elona Kogan, Esq., has been appointed as the new Chief Legal Officer. A search for a new Chief Financial Officer is underway. On July 29, 2024, the company issued a press release detailing these transitions.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement